A new generation of therapeutic and diagnostic technologies is making its way from research settings to clinical practice. They represent an ongoing transformation where manufacturers, regulators, and care providers must address a number of topics to live up to expectations, including clinical, regulatory, and market access hurdles, which have broader implications for health systems as a whole in terms of social and economic sustainability.
Looking broadly across the healthcare industry, there are five major forces at play that will likely shape the future of therapies:
- Smaller patient populations due to narrower stratification of subpopulations in more common tumour types.
- Shorter product life cycles, which have reduced by almost fivefold since the 1990s because of a more competitive landscape and faster innovation cycles.
- A new age of combination therapy and sources of innovation triggered by an increased level of external sourcing of innovation and collaboration especially among pharmaceutical and biotechnology companies.
- A significant shift in value across healthcare, partly driven and informed by big data, which in turn will enable more innovative access models.
- A new wave of medical technologies, providing tools to address a broader set of indications and offering a greater promise of personalized therapies.
Oliba can provide you with a comprehensive perspective on the clinical, regulatory, organizational, and financial impacts of the introduction of advanced therapies even before marketing authorization. We can also devise strategic programs to market innovative therapeutic and diagnostic technologies in certain settings (commercial strategy design and implementation, sales forecasting, institutional relationship with national or local authorities, communication and/or education campaigns etc).